Drugs and patents in ATC class L01EG - Mammalian target of rapamycin (mTOR) kinase inhibitors

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
TEMSIROLIMUS	temsirolimus
TORISEL	temsirolimus
AFINITOR DISPERZ	everolimus
EVEROLIMUS	everolimus
AFINITOR	everolimus
ZORTRESS	everolimus
HYFTOR	sirolimus
>Tradename	>Generic Name

Last updated: June 16, 2026

mTOR inhibitors in ATC Class L01EG include small-molecule kinase inhibitors that target the mTOR pathway, with commercialization concentrated in everolimus (multiple brands and generics), temsirolimus (largely single-origin at brand level), and sirolimus analogs used across oncology and transplant indications. Patent exposure is driven by (i) core compound patents, (ii) polymorph/formulation and process patents, (iii) indication-specific method-of-use claims, and (iv) exclusivity tied to approved labeling, with the fastest erosion in oncology combinations where branded exclusivities expire and Paragraph IV incentives increase.

Which mTOR inhibitors are included in ATC L01EG, and how do their markets differ?

Featured snippet: ATC L01EG is an oncology-focused grouping for mTOR kinase inhibitors. Market dynamics vary by molecule (everolimus, temsirolimus) and by indication mix (renal cell carcinoma, breast cancer, neuroendocrine tumors, mantle cell lymphoma, and transplantation), which in turn drives distinct patent cliffs and generic entry timing.

How do L01EG molecule-level sales and indication mix shape patent cliffs?

mTOR inhibitors are primarily differentiated by:

Active ingredient (everolimus vs temsirolimus vs rapalogs used in adjacent classifications depending on labeling and taxonomies).
Indication portfolio and intensity of combination therapy.
Whether new formulations and line extensions were pursued after initial approvals.

Key commercialization pattern:

Everolimus tends to have the broadest franchise footprint across oncology and requires a denser patent mosaic because of multiple formulation generations and multiple labeled indications.
Temsirolimus is often more limited in blockbuster scale versus everolimus, with patent strategy more sensitive to the original compound and manufacturing/process claims.

What therapeutic areas and combinations increase both revenue and IP complexity?

mTOR inhibitors are used in:

Solid tumors: RCC, breast cancer, neuroendocrine tumors.
Hematologic malignancies: mantle cell lymphoma (temsirolimus).
Combinations: mTOR plus endocrine therapy or VEGF/other pathway agents, creating method-of-use patent leverage and challenging “carve-out” design choices for generics.

What patents protect everolimus and temsirolimus in ATC L01EG?

Featured snippet: Core compound patents for everolimus and temsirolimus anchor the primary IP estate, followed by secondary protection on pharmaceutical forms, salts/solvates where applicable, manufacturing processes, and labeling-specific method-of-use claims.

What does the patent estate typically look like for everolimus?

Patent coverage for everolimus usually spans:

Compound class and specific structure claims (earliest priority, expiring earliest).
Crystalline/amorphous and polymorph claims for tablet or dispersible solid forms.
Drug product manufacturing/process claims (scale-up, granulation, solvent use, drying profiles, impurity controls).
Therapeutic use claims for specific cancers, lines of therapy, and combination regimens.

What does the patent estate typically look like for temsirolimus?

Temsirolimus tends to have:

Original compound and early formulation protection.
Process/manufacturing claims tied to lyophilization, concentration steps, and stability.
Indication-specific method-of-use claims less fragmented than everolimus, but still relevant for Paragraph IV positioning.

Which jurisdictions drive enforceability and market access?

For market dynamics, patent and exclusivity activity concentrates on:

U.S. (Orange Book listed patents and FDA exclusivity).
Europe (EMA and national EP enforcement).
UK, Canada, and select Asia markets where enforcement is strong or where import entry is constrained by patent injunction risk.

When does everolimus exclusivity and patent protection lose exclusivity?

Featured snippet: Everolimus’s exclusivity erosion follows a “stack” model: core compound patents end first, then secondary patents and indication-specific exclusivities expire, leaving a rolling window where generics can challenge specific listed patents rather than the entire brand portfolio at once.

How do Orange Book listed patents determine “first generic entry” versus “full generic coverage”?

For each approved product, the Orange Book lists:

Patent numbers tied to drug substance/drug product claims.
Patent numbers tied to methods of use.
Each listed patent’s expiration date and exclusivity linkage to prevent launch until expiry or successful challenge/waiver.

Market reality:

A generic may be able to launch in a single-dose form only if it can design around the specific listed patents and satisfy FDA labeling and bioequivalence requirements.
For a full coverage strategy, multiple ANDAs may be needed across strengths and dosage forms.

How does labeling evolution change the exclusivity timeline?

Everolimus has had multiple labeling expansions across oncology settings. When a new indication is added:

New method-of-use patents may be listed.
FDA exclusivity can delay approval for generics claiming the same label elements.

Net effect:

Timelines differ by indication within the same active ingredient.

When does temsirolimus lose exclusivity, and what launch barriers remain?

Featured snippet: Temsirolimus’s generic launch timing is driven by the expiration of the earliest compound patents and the remaining drug product and method-of-use patents listed for its approved presentations.

What launch scenarios tend to matter for temsirolimus generics?

Common scenarios:

Launch after expiration of the core listed patents but before all secondary method-of-use patents are cleared.
Paragraph IV challenges targeting only specific listed patents, with settlement agreements that may allocate launch dates and/or design-around obligations.

What does “design-around” look like in mTOR formulations?

Design-around generally means:

Changing solid form or processing parameters to avoid formulation/process patent coverage.
Narrowing label claims to non-infringing indications.
Adjusting dosing regimen text to avoid method-of-use claim coverage.

What patent litigation affects mTOR inhibitors, including Paragraph IV challenges?

Featured snippet: mTOR inhibitors are frequent targets for Paragraph IV challenges because their franchises are mature, Orange Book estates are layered, and multiple strengths/formulations create parallel launch opportunities.

What are the most common mTOR inhibitor litigation patterns?

Across mTOR inhibitor estates, litigation and settlements typically follow:

Multiple Paragraph IV filings against the same brand drug, each attacking different listed patents.
Early court rulings on whether claims are invalid or not infringed, shaping subsequent settlements.
Stipulated dismissal based on a negotiated launch date, sometimes with product design constraints.

How do settlements typically allocate risk for future generic entry?

Settlement patterns:

Brand pays for delay (reverse payment) or agrees to an earlier-than-broad expiry launch date for a generic challenger.
Generic agrees not to market certain versions or strengths until later dates.
Parties sometimes agree on “trigger” events tied to FDA approval, patent status, or launch readiness.

What formulations are protected for everolimus and temsirolimus?

Featured snippet: Formulation IP for mTOR inhibitors focuses on the physical state of the drug substance (polymorph/crystal form), the drug product manufacturing process, and stability and dissolution characteristics that affect bioavailability.

What formulation patent types are most likely to block generic switches?

For everolimus-style drug products:

Polymorph and solid-state form patents.
Tablet composition patents (excipient selection, ratios, coating).
Manufacturing process patents (granulation, milling, drying, solvent systems).
Sterility and stability process patents for injectable products where applicable (more prominent for temsirolimus presentations and other injectables).

Which strategy is used to avoid formulation infringement?

Generic design-around commonly includes:

Different solid form selection with comparable dissolution profile.
Alternate manufacturing route that preserves bioequivalence while avoiding specific process claim steps.
Label carve-outs to avoid method-of-use claims tied to specific regimens.

How strong is the patent estate for mTOR inhibitors, and what drives strength?

Featured snippet: Patent strength in mTOR inhibitors depends on how many Orange Book patents are listed per product and how many are “must-clear” before a meaningful launch. Estates are strongest when they include enforceable method-of-use claims that are difficult to carve out without losing the commercial label.

What metrics are most predictive for enforceability and launch risk?

High-risk portfolios show:

Large number of listed patents across drug substance, drug product, and method-of-use categories.
Patents with broad claim scope covering combination regimens.
Litigation history with outcomes that suggest validity is likely and infringement proofs are robust.

What reduces strength and accelerates launch?

Launch risk declines when:

The most important patents are narrowly claim-limited.
Courts narrow claim interpretation, enabling easier non-infringing designs.
Critical patents expire early relative to the intended commercial timing.

What is the Orange Book status of mTOR inhibitors, and how does it affect generic timing?

Featured snippet: Orange Book status governs which patents a generic must address to file an ANDA with the intended label. The number of “patent walls” (drug substance, drug product, method-of-use) determines practical launch dates even after FDA approval.

How to interpret Orange Book listings for commercialization planning

For a generic entrant, key decision factors are:

Whether the ANDA can be approved with a label that avoids non-infringement.
Which listed patents are targeted by Paragraph IV (and which remain unchallenged).
Whether a settlement resolves only certain patents or provides broad clearance.

How does Orange Book status differ by dosage form and strength?

For each active ingredient:

Each NDC strength and dosage form can have distinct patent listings.
A generic may face different listed patents depending on the formulation platform.

Which companies are positioned for mTOR inhibitor generics, and what are their risks?

Featured snippet: Generic entry tends to cluster among large ANDA players with established litigation capacity, because mTOR estates typically require multi-patent management and label engineering.

What competitive advantage do experienced ANDA filers have?

They can:

File across multiple strengths/dosage forms to maximize early market capture.
Run parallel Paragraph IV attacks on different listed patents to increase settlement leverage.
Prepare manufacturing design-around strategies aligned with court claim interpretations.

What are the commercial risks for entrants?

Common risks:

Settlements that delay launch beyond initial FDA approval timeline.
Invalidation failures on key patents leading to injunction threats.
Inability to maintain approved label scope without losing significant sales.

How do revenue exposure and payer dynamics interact with the IP landscape?

Featured snippet: Revenue exposure in mTOR inhibitors is concentrated in oncology settings with high treatment adherence, and payer adoption typically depends on formulary access post-expiry or post-settlement launch. The IP landscape determines the timing and label scope of generic entry, which then determines market share capture.

How payer and hospital contracting schedules shape launch impact

Hospitals and oncology networks often adopt generics in step with tender cycles.
Delays caused by litigation or market-exclusivity constraints can shift share capture to later quarters.

What matters for investors and licensors?

The magnitude of “must-clear” patents and whether settlements extend delay.
Likely price erosion once multiple strengths and dosage forms become generic-available.
Brand retention for non-carved-out indications.

How does everolimus compare with temsirolimus on patent and generic entry pressure?

Featured snippet: Everolimus faces broader competitive pressure because its franchise spans multiple indications and has a denser secondary patent portfolio. Temsirolimus is more likely to see fewer, more concentrated barriers, tied to injectable product IP and original compound/method-of-use claims.

Patent estate complexity comparison

Everolimus: more layered, more label expansions, more polymorph/formulation/process variants, more method-of-use listing opportunities.
Temsirolimus: fewer product platforms at brand level, but injectables can carry stronger manufacturing/stability barriers.

Commercial pressure comparison

Everolimus: multiple generic entrants can fight for share as soon as key Orange Book patents clear.
Temsirolimus: fewer entrants can still gain meaningful share if they can clear injectables and maintain label alignment.

Key takeaways

mTOR inhibitor market dynamics are determined by an Orange Book “stack” of drug substance, drug product, and method-of-use patents, plus FDA exclusivity tied to labeling evolution.
Everolimus generally carries a denser and more litigated patent estate than temsirolimus due to broader oncology indication coverage and multi-generation formulation/process protection.
Generic entry risk is highest when method-of-use patents cover combination regimens that are required to preserve commercial label and sales volume.
Patent litigation and settlements typically allocate partial clearance across strengths, dosage forms, and indications rather than providing full blanket freedom to operate.
For commercialization planning, the practical launch date is driven less by first compound expiry and more by the last must-clear listed patents for each relevant dosage form and label indication.

FAQs

What patents are most likely to be Orange Book-listed for everolimus tablets versus everolimus dispersible forms?
Which ATC L01EG mTOR inhibitors are most exposed to Paragraph IV challenges based on mature franchise timelines?
How do method-of-use patents for mTOR inhibitors affect generic label design and carved-out indications?
What manufacturing or solid-state design changes typically help ANDA applicants avoid formulation/process infringement for mTOR kinase inhibitors?
How do settlement agreements in mTOR inhibitor patent cases usually govern launch dates across multiple strengths and dosage forms?

References

FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
EMA. European Medicines Agency: product information and EPAR documents for relevant mTOR inhibitor products. European Medicines Agency. https://www.ema.europa.eu/
FDA. ANDA Product-Specific Guidance and regulatory pathways. U.S. Food and Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda